本文選題：急性冠狀動(dòng)脈綜合征　切入點(diǎn)：生長(zhǎng)分化因子　出處：《中國(guó)動(dòng)脈硬化雜志》2017年05期 　論文類型：期刊論文

【摘要】：目的評(píng)估生長(zhǎng)分化因子15(GDF-15)對(duì)急性冠狀動(dòng)脈綜合征(ACS)患者中期預(yù)后的預(yù)測(cè)價(jià)值。方法連續(xù)入選95例急性冠狀動(dòng)脈綜合征患者,采用酶聯(lián)免疫吸附雙抗體夾心法(ELISA)測(cè)定血漿GDF-15濃度,根據(jù)GDF-15中位數(shù)分為低濃度組和高濃度組,對(duì)出院患者進(jìn)行定期隨訪,分別計(jì)算并比較2組患者的中期生存率以及主要不良心臟事件(MACE)發(fā)生率。生存率評(píng)估采用生存分析法。使用受試者工作特征(ROC)曲線分析GDF-15濃度對(duì)ACS患者的中期預(yù)后的預(yù)測(cè)價(jià)值。結(jié)果 ACS患者GDF-15濃度為921.56±462.20 ng/L,共隨訪患者95例,平均隨訪時(shí)間33.76±6.29月,死亡4例。生存分析提示GDF-15高濃度組患者的生存率低于GDF-15低濃度組(P=0.039)。GDF-15評(píng)估ACS患者中期生存的ROC曲線下面積(AUC)為0.853(SE=0.074,P=0.017,95%CI0.708~0.998),而GDF-15在預(yù)測(cè)ACS患者中期發(fā)生MACE的ROC曲線下面積為0.805(SE=0.068,P=0.000,95%CI 0.672~0.938)。結(jié)論 GDF-15可反映ACS患者的中期預(yù)后,作為一個(gè)有潛力的新標(biāo)志物,能更好地幫助ACS患者進(jìn)行危險(xiǎn)分層及評(píng)估預(yù)后。
[Abstract]:Objective to evaluate the prognostic value of growth differentiation factor 15 (GDF-15) in patients with acute coronary syndrome (ACS). Methods 95 consecutive patients with acute coronary syndrome (ACS) were enrolled and plasma GDF-15 levels were measured by Elisa double antibody sandwich method. According to the median of GDF-15, the patients were divided into low concentration group and high concentration group. The medium-term survival rate and the incidence of major adverse cardiac events in the two groups were calculated and compared. Survival analysis was used to evaluate the survival rate. The medium-term preconditioning of GDF-15 concentration in ACS patients was analyzed by using the operating characteristics of the subjects. Results the concentration of GDF-15 in patients with ACS was 921.56 鹵462.20 ng / L, and 95 patients were followed up. The mean follow-up time was 33.76 鹵6.29 months. Survival analysis showed that the survival rate of patients with high concentration of GDF-15 was lower than that of patients with low GDF-15 concentration. The area under the ROC curve for evaluating the medium-term survival of patients with ACS was 0.853SE-0.074%. The area under the ROC curve of GDF-15 in predicting MACE in ACS patients was 0.708% 0.998g. Conclusion GDF-15 can reflect the medium-term prognosis of patients with ACS. As a potential new marker, it can better help ACS patients to carry out risk stratification and evaluate prognosis.
【作者單位】： 南京醫(yī)科大學(xué)附屬常州市第二人民醫(yī)院心內(nèi)科;
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 魯鋒;;生長(zhǎng)分化因子-15在心血管疾病中的研究進(jìn)展[J];醫(yī)學(xué)信息(中旬刊);2010年12期

2 張s，

本文編號(hào)：1644744